Video Experimental Relacionado
Updated: May 12, 2026

08:59
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.5K
Informe de caso: Respuesta profunda y duradera al talazoparib en el carcinoma rectal neuroendocrino con mutación
Milan Khealani1, Byoung Uk Park2, Robben Schat3
1Division of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN, United States.
Frontiers in oncology
|January 5, 2026
Resumen
No abstract available in PubMed .
Palabras clave:
Inhibidor de la PARPInforme de casomutación gBRCA2Carcinoma rectal y neuroendocrinoTalazoparib es un fármacoMás Videos Relacionados
Videos de Conceptos Relacionados
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

